CO6251324A2 - Proceso de purificacion abreviado para la produccion de polisacaridos streptococcus pneumoniae en capsulas - Google Patents

Proceso de purificacion abreviado para la produccion de polisacaridos streptococcus pneumoniae en capsulas

Info

Publication number
CO6251324A2
CO6251324A2 CO09117278A CO09117278A CO6251324A2 CO 6251324 A2 CO6251324 A2 CO 6251324A2 CO 09117278 A CO09117278 A CO 09117278A CO 09117278 A CO09117278 A CO 09117278A CO 6251324 A2 CO6251324 A2 CO 6251324A2
Authority
CO
Colombia
Prior art keywords
solution
producing
purified
cell lysate
retained material
Prior art date
Application number
CO09117278A
Other languages
English (en)
Spanish (es)
Inventor
Yonghui Yuan
Mark Ruppen
Wei-Chuan Sun
John S Simpson
Justin Keith Moran
Pamela Charbonneau
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39712482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6251324(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CO6251324A2 publication Critical patent/CO6251324A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • C07H1/08Separation; Purification from natural products
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/04Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087Polysaccharides; Lipopolysaccharides [LPS]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Sustainable Development (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CO09117278A 2007-03-23 2009-10-20 Proceso de purificacion abreviado para la produccion de polisacaridos streptococcus pneumoniae en capsulas CO6251324A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89661607P 2007-03-23 2007-03-23

Publications (1)

Publication Number Publication Date
CO6251324A2 true CO6251324A2 (es) 2011-02-21

Family

ID=39712482

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09117278A CO6251324A2 (es) 2007-03-23 2009-10-20 Proceso de purificacion abreviado para la produccion de polisacaridos streptococcus pneumoniae en capsulas

Country Status (29)

Country Link
US (3) US8652480B2 (https=)
EP (3) EP2436700B8 (https=)
JP (5) JP5688902B2 (https=)
KR (2) KR20150021127A (https=)
CN (1) CN101663327B (https=)
AU (1) AU2008231041B2 (https=)
BR (1) BRPI0809212B8 (https=)
CA (1) CA2681570C (https=)
CL (2) CL2008000831A1 (https=)
CO (1) CO6251324A2 (https=)
CR (1) CR11041A (https=)
DK (3) DK2129693T3 (https=)
EC (1) ECSP099652A (https=)
ES (3) ES2677353T3 (https=)
GT (1) GT200900249A (https=)
HN (1) HN2009001965A (https=)
HU (3) HUE031567T2 (https=)
IL (1) IL201106A (https=)
MX (1) MX2009010221A (https=)
MY (1) MY150927A (https=)
NI (1) NI200900172A (https=)
NZ (1) NZ580134A (https=)
PL (3) PL3406635T3 (https=)
PT (3) PT2129693T (https=)
RU (1) RU2516340C2 (https=)
SI (3) SI2436700T1 (https=)
UA (1) UA99278C2 (https=)
WO (1) WO2008118752A2 (https=)
ZA (1) ZA200906625B (https=)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101663327B (zh) * 2007-03-23 2014-05-07 惠氏公司 产生肺炎链球菌(streptococcus pneumoniae)荚膜多糖的缩短的纯化方法
GB0818453D0 (en) * 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CA2777837C (en) * 2008-10-27 2017-07-11 Novartis Ag Purification method
BRPI0922981A8 (pt) * 2008-12-18 2019-11-26 Wyeth Llc método para o controle do peso molecular polissacarídeo para o sorotipo 19a de streptococcus pneumoniae
ES2749952T3 (es) * 2008-12-18 2020-03-24 Wyeth Llc Procedimiento de control del peso molecular de polisacáridos de Streptococcus pneumoniae usando carbono
US20120052088A1 (en) 2009-04-30 2012-03-01 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
US20110262989A1 (en) 2010-04-21 2011-10-27 Nanomr, Inc. Isolating a target analyte from a body fluid
US9476812B2 (en) 2010-04-21 2016-10-25 Dna Electronics, Inc. Methods for isolating a target analyte from a heterogeneous sample
US8841104B2 (en) 2010-04-21 2014-09-23 Nanomr, Inc. Methods for isolating a target analyte from a heterogeneous sample
WO2011145108A2 (en) * 2010-05-15 2011-11-24 Serum Institute Of India Ltd. Purification of capsular polysaccharides
BR112013024322B1 (pt) * 2011-03-22 2020-04-22 Serum Inst India Ltd processo para preparação de polissacarídeos
CN102660601B (zh) * 2012-04-17 2015-10-28 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
CN102660603B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 一种快速纯化细菌荚膜多糖的方法
CN102660602B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
US9650411B2 (en) * 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
RU2606022C2 (ru) * 2012-09-07 2017-01-10 Ск Кемикалс Ко., Лтд. Способ получения капсульного полисахарида с пневмококковым серотипом
RU2015106791A (ru) 2012-10-03 2016-11-20 Глэксосмитиклайн Байолоджикалз Са Иммуногенные композиции
US9551704B2 (en) 2012-12-19 2017-01-24 Dna Electronics, Inc. Target detection
US10000557B2 (en) 2012-12-19 2018-06-19 Dnae Group Holdings Limited Methods for raising antibodies
US9995742B2 (en) 2012-12-19 2018-06-12 Dnae Group Holdings Limited Sample entry
US9434940B2 (en) 2012-12-19 2016-09-06 Dna Electronics, Inc. Methods for universal target capture
US9599610B2 (en) 2012-12-19 2017-03-21 Dnae Group Holdings Limited Target capture system
US9804069B2 (en) 2012-12-19 2017-10-31 Dnae Group Holdings Limited Methods for degrading nucleic acid
US9910041B2 (en) 2013-07-12 2018-03-06 Emd Millipore Corporation Method of determining virus removal from a sample containing a target protein using activated carbon
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN110859957B (zh) 2014-01-21 2024-04-12 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
BR112016015835B1 (pt) 2014-01-21 2023-12-26 Pfizer Inc Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
PL3096786T3 (pl) 2014-01-21 2021-11-08 Pfizer Inc. Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
HUE062499T2 (hu) 2015-01-15 2023-11-28 Pfizer Pneumococcus-vakcinákban történõ alkalmazásra szolgáló immunogén készítmények
MY182282A (en) 2015-05-04 2021-01-18 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
WO2016204265A1 (ja) * 2015-06-18 2016-12-22 一般財団法人阪大微生物病研究会 肺炎球菌補体依存性殺菌能測定方法
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
CN105131139B (zh) * 2015-07-31 2018-02-13 兰州生物制品研究所有限责任公司 一种肺炎链球菌荚膜多糖的纯化方法
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
CA3031799A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3031797A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN110366428B (zh) 2016-12-30 2024-05-17 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
BR112019014833A2 (pt) 2017-01-20 2020-04-14 Pfizer composições imunogênicas para uso em vacinas pneumococais
EP4656208A3 (en) 2017-01-31 2026-03-04 Merck Sharp & Dohme LLC Methods for making polysaccharide-protein conjugates
CN110225757A (zh) 2017-01-31 2019-09-10 默沙东公司 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
MX2019009869A (es) 2017-02-24 2019-10-02 Merck Sharp & Dohme Formulaciones de vacunas de conjugado de neumococos.
JP7680185B2 (ja) 2017-02-24 2025-05-20 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎連鎖球菌多糖-タンパク質コンジュゲートの免疫原性の増強
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
WO2018227177A1 (en) 2017-06-10 2018-12-13 Inventprise, Llc Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
US10702596B2 (en) 2017-07-05 2020-07-07 Inventprise, Llc Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography
JP7111799B2 (ja) * 2017-07-05 2022-08-02 インベントプライズ リミテッド ライアビリティ カンパニー 溶菌酵素、接線流濾過、及びマルチモードクロマトグラフィを用いたワクチン生産のための多糖精製
MX394768B (es) 2017-09-07 2025-03-21 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina.
CN111093650B (zh) 2017-09-07 2024-03-01 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
MX394767B (es) 2017-09-07 2025-03-24 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
CN107936128B (zh) * 2017-11-22 2020-07-03 成都欧林生物科技股份有限公司 一种简便有效的细菌疫苗纯化方法
ES3058336T3 (es) 2017-12-06 2026-03-10 Merck Sharp & Dohme Llc Composiciones que comprenden conjugados polisacárido-proteína de Streptococcus pneumoniae y métodos de uso de los mismos
BR112020014978A2 (pt) 2018-02-05 2020-12-22 Sanofi Pasteur, Inc. Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
EP3749357A4 (en) 2018-02-05 2022-04-20 Sanofi Pasteur, Inc. POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE PROTEIN CONJUGATE COMPOSITION
EP3788143B1 (en) 2018-04-30 2023-06-28 Merck Sharp & Dohme LLC Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
US12144855B2 (en) 2018-04-30 2024-11-19 Merck Sharp & Dohme Llc Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
EP3787673A4 (en) 2018-04-30 2022-04-27 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
DK3817775T3 (da) 2018-07-04 2024-09-16 Vaxcyte Inc Forbedringer i immunogene konjugater
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
EP3824019A1 (en) * 2018-07-19 2021-05-26 GlaxoSmithKline Biologicals SA Processes for preparing dried polysaccharides
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
CR20210333A (es) 2018-12-19 2021-08-18 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
JP7239509B6 (ja) * 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
PH12022550110A1 (en) 2019-07-31 2022-12-12 Sk Bioscience Co Ltd Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
US12473379B2 (en) * 2019-09-06 2025-11-18 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
CN119371566A (zh) 2020-02-21 2025-01-28 辉瑞公司 糖类的纯化
JP2023528657A (ja) * 2020-06-12 2023-07-05 ビーエーエスエフ ソシエタス・ヨーロピア 発酵ブロスの改善された脱塩及び例えばオリゴ糖のファインケミカルの精製
WO2022035816A1 (en) 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
KR20230056727A (ko) 2020-08-26 2023-04-27 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
GB202016165D0 (en) 2020-10-12 2020-11-25 Optivalent Ltd Vaccine
WO2022084852A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
CA3200602A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
JP7804673B2 (ja) 2020-11-10 2026-01-22 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
JP2024517780A (ja) 2021-05-03 2024-04-23 ファイザー・インク 細菌およびベータコロナウイルス感染症に対するワクチン接種
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
JP2024521847A (ja) 2021-05-28 2024-06-04 ファイザー・インク コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用
MX2023013434A (es) 2021-05-28 2023-12-12 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
CA3247998A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
GB2614916A (en) 2022-01-25 2023-07-26 Optivalent Ltd Intradermal vaccine complement
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
EP4622665A2 (en) 2022-11-22 2025-10-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2023403045A1 (en) 2022-12-01 2025-06-12 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20252774A1 (es) 2023-03-30 2025-12-22 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
AU2024255922A1 (en) 2023-04-14 2025-10-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121532194A (zh) 2023-05-18 2026-02-13 默沙东有限责任公司 用于肺炎球菌疫苗的化合物及佐剂制剂
KR20260015203A (ko) 2023-05-19 2026-02-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 호흡기 세포융합 바이러스 및 스트렙토코쿠스 뉴모니아에 감염에 대한 면역 반응을 유발하는 방법
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002004B1 (en) 1977-11-07 1982-03-24 Ciba-Geigy Ag Process for the manufacture of fluorinated cationic compounds and their use as surfactants
CA1115210A (en) * 1977-11-28 1981-12-29 Dennis J. Carlo Pneumococcal vaccine
US4221906A (en) * 1979-03-19 1980-09-09 American Cyanamid Company Stabilization of pneumococcal polysaccharides
US4242501A (en) * 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
FR2495939B1 (fr) * 1980-12-11 1985-10-11 Merieux Inst Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
JPS6170994A (ja) * 1984-09-14 1986-04-11 Daikin Ind Ltd 環状(1→2)−β−D−グルカンの製法
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5714354A (en) * 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
RU2087156C1 (ru) * 1995-06-22 1997-08-20 Леонид Николаевич Падюков Вакцина против пневмококковой инфекции
KR100757630B1 (ko) * 1997-12-23 2007-09-10 박스터 헬쓰케어 에스.에이. 신규한 추출 및 단리 방법으로 수득되는 세균성 캡슐형 다당류
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
GB0108079D0 (en) * 2001-03-30 2001-05-23 Microbial Technics Ltd Protein
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CN101155833B (zh) * 2005-04-08 2011-04-20 惠氏公司 通过pH操作将污染物与肺炎链球菌多糖分离
EP3311836A1 (en) * 2005-04-08 2018-04-25 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN101663327B (zh) * 2007-03-23 2014-05-07 惠氏公司 产生肺炎链球菌(streptococcus pneumoniae)荚膜多糖的缩短的纯化方法

Also Published As

Publication number Publication date
JP6872649B2 (ja) 2021-05-19
HUE059085T2 (hu) 2022-10-28
CL2008000831A1 (es) 2008-07-04
BRPI0809212B8 (pt) 2021-05-25
US20140363463A1 (en) 2014-12-11
GT200900249A (es) 2010-07-28
CN101663327B (zh) 2014-05-07
WO2008118752A2 (en) 2008-10-02
HUE039169T2 (hu) 2018-12-28
SI2129693T1 (sl) 2017-01-31
HUE031567T2 (hu) 2017-07-28
DK2436700T5 (en) 2018-09-03
JP2017141263A (ja) 2017-08-17
HN2009001965A (es) 2011-10-06
BRPI0809212A2 (pt) 2014-09-02
JP2020169160A (ja) 2020-10-15
IL201106A0 (en) 2010-05-17
JP2010521972A (ja) 2010-07-01
US8999697B2 (en) 2015-04-07
ES2677353T8 (es) 2018-09-25
PL2129693T3 (pl) 2017-07-31
CA2681570C (en) 2016-05-03
DK2436700T3 (en) 2018-08-13
EP3406635A1 (en) 2018-11-28
KR101500771B1 (ko) 2015-03-18
ZA200906625B (en) 2010-07-28
PT2129693T (pt) 2017-02-14
EP2436700B8 (en) 2018-08-01
MY150927A (en) 2014-03-14
SI3406635T1 (sl) 2022-08-31
NI200900172A (es) 2010-09-07
AU2008231041A8 (en) 2009-11-12
AU2008231041B2 (en) 2013-03-07
PT3406635T (pt) 2022-07-08
RU2516340C2 (ru) 2014-05-20
WO2008118752A3 (en) 2008-11-20
IL201106A (en) 2014-04-30
ECSP099652A (es) 2009-10-30
CL2017002029A1 (es) 2018-05-18
EP2436700A1 (en) 2012-04-04
DK3406635T3 (da) 2022-05-30
ES2922132T3 (es) 2022-09-08
EP3406635B1 (en) 2022-05-11
BRPI0809212B1 (pt) 2019-06-18
PL2436700T3 (pl) 2018-12-31
JP5688902B2 (ja) 2015-03-25
MX2009010221A (es) 2009-10-19
AU2008231041A1 (en) 2008-10-02
CR11041A (es) 2009-12-30
PL3406635T3 (pl) 2022-08-22
EP2436700B1 (en) 2018-06-20
JP2019048844A (ja) 2019-03-28
CA2681570A1 (en) 2008-10-02
US20080286838A1 (en) 2008-11-20
CN101663327A (zh) 2010-03-03
US8652480B2 (en) 2014-02-18
ES2677353T3 (es) 2018-08-01
UA99278C2 (ru) 2012-08-10
ES2614249T3 (es) 2017-05-30
EP2129693A2 (en) 2009-12-09
US9675681B2 (en) 2017-06-13
NZ580134A (en) 2011-10-28
JP6825950B2 (ja) 2021-02-03
DK2129693T3 (en) 2017-02-13
EP2129693B1 (en) 2016-12-07
US20150165017A1 (en) 2015-06-18
KR20150021127A (ko) 2015-02-27
RU2009135485A (ru) 2011-04-27
SI2436700T1 (sl) 2018-09-28
KR20100015765A (ko) 2010-02-12
PT2436700T (pt) 2018-07-17
HK1141815A1 (en) 2010-11-19
JP2015143225A (ja) 2015-08-06

Similar Documents

Publication Publication Date Title
CO6251324A2 (es) Proceso de purificacion abreviado para la produccion de polisacaridos streptococcus pneumoniae en capsulas
AU2006234984B2 (en) Separation of contaminants from Streptococcus pneumoniae polysaccharide by pH manipulation
FI79346B (fi) Framstaellning av hyaluronsyra medelst bakteriekultur.
ZA200904482B (en) Polyelectrolyte precipitation and purification of antibodies
CN102382177B (zh) 恩拉霉素的提取分离和纯化方法
CA2553640C (en) Novel canola protein isolate
CN103304626B (zh) 一种分级提取蓝藻胞外聚合物的方法
CN103058834B (zh) 一种从天然橡胶制胶废水中提取白坚木皮醇的方法
ITMI20121184A1 (it) Processo per la produzione industriale di ialuronato di sodio (hana) altamente purificato a peso molecolare controllato
CN102603478B (zh) 从赤藓糖醇多次结晶后的母液中分离提纯赤藓糖醇的方法
MX2020000224A (es) Purificacion de polisacárido para la produccion de vacuna utilizando enzimas líticas, filtración de flujo tangencial y cromatografía multimodal.
KR101638662B1 (ko) 히알루론산 및/또는 그의 염의 정제 방법
CN102838624B (zh) 一种从发酵液中纯化克拉维酸的方法
PE20060499A1 (es) Procedimiento de produccion de polisacarido k5
CN102174063B (zh) 一种低聚唾液酸的制备方法
CN102040667B (zh) 海参多糖中蛋白的生物脱除方法
CN103319627A (zh) 一种对透明质酸钠进行分子量分级的方法
CN102803299A (zh) 透明质酸的提纯方法以及制造方法
JP2015517313A5 (https=)
CN101676307A (zh) 一种透明质酸钠提纯优化的方法
CN106367451A (zh) 一种a群c群脑膜炎球菌多糖的制备方法
JP2002095493A (ja) 酢酸菌の菌膜を形成する多糖及びその精製方法
TW201522622A (zh) 用於製備肺炎鏈球菌血清型之莢膜多醣的方法
CN103360470A (zh) 一种雷莫拉宁发酵液的纯化方法
CN103342760A (zh) 一种从微生物发酵液中制备透明质酸的方法

Legal Events

Date Code Title Description
FG Application granted